Calidi Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
CLDI$0.73+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands except for par value data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $1,897 | $1,949 |
| Prepaid expenses and other current assets | 324 | 2,354 |
| Total current assets | 2,221 | 4,303 |
| NONCURRENT ASSETS | ||
| Machinery and equipment, net | 982 | 1,270 |
| Operating lease right-of-use assets, net | 3,237 | 4,073 |
| Other noncurrent assets | 217 | 373 |
| TOTAL ASSETS | $6,657 | $10,019 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $3,574 | $2,796 |
| Related party accounts payable | — | 81 |
| Accrued expenses and other current liabilities | 2,567 | 4,896 |
| Related party accrued expenses and other current liabilities | 496 | 536 |
| Term notes payable, net of discount, including accrued interest | 242 | 529 |
| Related party term notes payable, net of discount, including accrued interest | 2,631 | 278 |
| Related party bridge loan payable, including accrued interest | 217 | — |
| Related party other current liability | 620 | — |
| Finance lease liability, current | 69 | 81 |
| Operating lease right-of-use liability, current | 1,163 | 1,035 |
| Total current liabilities | 11,579 | 10,232 |
| NONCURRENT LIABILITIES | ||
| Operating lease right-of-use liability, noncurrent | 2,161 | 3,037 |
| Finance lease liability, noncurrent | 166 | 216 |
| Warrant liability | 163 | 623 |
| Related party warrant liability | 13 | 48 |
| Convertible notes payable, including accrued interest | 1,773 | — |
| Related party term notes payable, net of discount, including accrued interest | — | 2,060 |
| Promissory note | 600 | — |
| Other noncurrent liabilities | — | 1,500 |
| Related party other noncurrent liabilities | — | 538 |
| TOTAL LIABILITIES | 16,455 | 18,254 |
| Commitments and contingencies (Note 11) | ||
| STOCKHOLDERS’ DEFICIT | ||
| Common stock, $0.0001 par value, 330,000 shares authorized; 9,311 and 3,552 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 1 | 1 |
| Additional paid-in capital | 107,408 | 91,383 |
| Non-controlling interest | 485 | — |
| Accumulated other comprehensive loss, net of tax | (74) | (47) |
| Accumulated deficit | (117,618) | (99,572) |
| Total stockholders’ deficit | (9,798) | (8,235) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $6,657 | $10,019 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.